HUE049611T2 - Ciklikus éter-pirazol-4-il-heterociklil-karboxamid vegyületek és felhasználási módszerek - Google Patents
Ciklikus éter-pirazol-4-il-heterociklil-karboxamid vegyületek és felhasználási módszerekInfo
- Publication number
- HUE049611T2 HUE049611T2 HUE13770441A HUE13770441A HUE049611T2 HU E049611 T2 HUE049611 T2 HU E049611T2 HU E13770441 A HUE13770441 A HU E13770441A HU E13770441 A HUE13770441 A HU E13770441A HU E049611 T2 HUE049611 T2 HU E049611T2
- Authority
- HU
- Hungary
- Prior art keywords
- heterocyclyl
- methods
- cyclic ether
- carboxamide compounds
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261705791P | 2012-09-26 | 2012-09-26 | |
US201361864882P | 2013-08-12 | 2013-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE049611T2 true HUE049611T2 (hu) | 2020-09-28 |
Family
ID=49261521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13770441A HUE049611T2 (hu) | 2012-09-26 | 2013-09-25 | Ciklikus éter-pirazol-4-il-heterociklil-karboxamid vegyületek és felhasználási módszerek |
Country Status (28)
Country | Link |
---|---|
US (2) | US9328106B2 (hu) |
EP (1) | EP2900657B1 (hu) |
JP (2) | JP6666147B2 (hu) |
KR (1) | KR102281288B1 (hu) |
CN (1) | CN104640858B (hu) |
AU (2) | AU2013322736A1 (hu) |
BR (1) | BR112015006019B1 (hu) |
CA (1) | CA2881068C (hu) |
CL (1) | CL2015000530A1 (hu) |
CR (1) | CR20150119A (hu) |
DK (1) | DK2900657T3 (hu) |
EA (1) | EA031622B1 (hu) |
ES (1) | ES2791648T3 (hu) |
HK (1) | HK1206737A1 (hu) |
HR (1) | HRP20200681T1 (hu) |
HU (1) | HUE049611T2 (hu) |
IL (1) | IL237159A0 (hu) |
LT (1) | LT2900657T (hu) |
MX (1) | MX2015003513A (hu) |
PE (1) | PE20151375A1 (hu) |
PH (1) | PH12015500488A1 (hu) |
PL (1) | PL2900657T3 (hu) |
PT (1) | PT2900657T (hu) |
RS (1) | RS60202B1 (hu) |
SG (1) | SG11201502343RA (hu) |
SI (1) | SI2900657T1 (hu) |
UA (1) | UA119229C2 (hu) |
WO (1) | WO2014048939A1 (hu) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR102091894B1 (ko) * | 2012-05-03 | 2020-03-20 | 제넨테크, 인크. | Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
WO2013174962A1 (en) | 2012-05-25 | 2013-11-28 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
KR102311840B1 (ko) | 2013-01-15 | 2021-10-14 | 인사이트 홀딩스 코포레이션 | Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물 |
JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
WO2015140189A1 (en) * | 2014-03-18 | 2015-09-24 | F. Hoffmann-La Roche Ag | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
SG11201707752SA (en) | 2015-04-22 | 2017-11-29 | Rigel Pharmaceuticals Inc | Pyrazole compounds and method for making and using the compounds |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
CN105254624B (zh) * | 2015-09-18 | 2019-08-09 | 上海吉铠医药科技有限公司 | 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用 |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PT3377488T (pt) | 2015-11-19 | 2022-11-21 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PT3472167T (pt) | 2016-06-20 | 2022-11-11 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
GEP20227428B (en) | 2016-12-22 | 2022-10-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
PE20200005A1 (es) | 2016-12-22 | 2020-01-06 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
CR20240101A (es) | 2018-03-08 | 2024-05-24 | Incyte Corp | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464) |
CA3095758A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP7328995B2 (ja) | 2018-05-11 | 2023-08-17 | インサイト・コーポレイション | Pd-l1免疫調節剤としてのテトラヒドロ-イミダゾ[4,5-c]ピリジン誘導体 |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
CA3152264A1 (en) | 2019-08-30 | 2021-03-04 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
US11414412B2 (en) | 2019-09-11 | 2022-08-16 | Genentech, Inc. | Process for the preparation of a medicament |
CA3155852A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS |
EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
CR20220299A (es) | 2019-12-20 | 2022-08-05 | Pfizer | Derivados de becimidazol |
EP3967307A1 (en) * | 2020-09-15 | 2022-03-16 | Instytut Hematologii I Transfuzologii | Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
CN112852960A (zh) * | 2020-12-09 | 2021-05-28 | 浙江省肿瘤医院 | 一种甲状腺乳头状癌生物标记物及其应用 |
CN112625030A (zh) * | 2020-12-25 | 2021-04-09 | 杭州澳赛诺生物科技有限公司 | 一种一锅法合成n-保护3-溴代吡唑的合成方法 |
WO2023202563A1 (en) * | 2022-04-18 | 2023-10-26 | Newbay Technology Development Co., Ltd. | Akt inhibitor in combination with pim kinase inhibitor |
WO2024082724A1 (en) * | 2022-10-17 | 2024-04-25 | Ningbo Newbay Technology Development Co., Ltd. | Pim kinase inhibitor in combination with kras inhibitor |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5831108A (en) | 1995-08-03 | 1998-11-03 | California Institute Of Technology | High metathesis activity ruthenium and osmium metal carbene complexes |
JPH1153696A (ja) | 1997-07-31 | 1999-02-26 | Toyota Motor Corp | カーブ路警報装置 |
US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US8828902B2 (en) | 2001-07-12 | 2014-09-09 | Reaxa Limited | Microencapsulated catalyst methods of preparation and method of use thereof |
EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US8318735B2 (en) * | 2006-10-31 | 2012-11-27 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
BRPI0808523A2 (pt) * | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | Inibidores de pim cinase e métodos de seu uso |
JP5591714B2 (ja) | 2007-12-12 | 2014-09-17 | マサチューセッツ インスティテュート オブ テクノロジー | 遷移金属触媒によるクロスカップリングのためのリガンド、およびその使用方法 |
UY31679A1 (es) | 2008-03-03 | 2009-09-30 | Inhibidores de cinasa pim y metodos para su uso | |
NZ590542A (en) * | 2008-06-19 | 2012-12-21 | Xcovery Holding Co Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
GEP20135849B (en) | 2008-09-02 | 2013-06-10 | Novartis Ag | Picolinamide derivatives as kinase inhibitors |
RU2015104301A (ru) | 2009-09-28 | 2015-11-10 | Ф.Хоффманн-Ля Рош Аг | Бензоксепиновые ингибиторы р13 и способы применения |
JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
AU2011237936A1 (en) * | 2010-04-07 | 2012-10-11 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
US20130109682A1 (en) * | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
BR112014007203A2 (pt) | 2011-09-27 | 2017-06-13 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção |
-
2013
- 2013-09-25 WO PCT/EP2013/069892 patent/WO2014048939A1/en active Application Filing
- 2013-09-25 HU HUE13770441A patent/HUE049611T2/hu unknown
- 2013-09-25 US US14/036,160 patent/US9328106B2/en active Active
- 2013-09-25 MX MX2015003513A patent/MX2015003513A/es active IP Right Grant
- 2013-09-25 PT PT137704417T patent/PT2900657T/pt unknown
- 2013-09-25 LT LTEP13770441.7T patent/LT2900657T/lt unknown
- 2013-09-25 CN CN201380048262.9A patent/CN104640858B/zh active Active
- 2013-09-25 KR KR1020157007625A patent/KR102281288B1/ko active IP Right Grant
- 2013-09-25 PE PE2015000409A patent/PE20151375A1/es unknown
- 2013-09-25 DK DK13770441.7T patent/DK2900657T3/da active
- 2013-09-25 SI SI201331721T patent/SI2900657T1/sl unknown
- 2013-09-25 EA EA201590624A patent/EA031622B1/ru not_active IP Right Cessation
- 2013-09-25 PL PL13770441T patent/PL2900657T3/pl unknown
- 2013-09-25 CA CA2881068A patent/CA2881068C/en active Active
- 2013-09-25 BR BR112015006019-6A patent/BR112015006019B1/pt active IP Right Grant
- 2013-09-25 JP JP2015532459A patent/JP6666147B2/ja active Active
- 2013-09-25 UA UAA201503792A patent/UA119229C2/uk unknown
- 2013-09-25 RS RS20200475A patent/RS60202B1/sr unknown
- 2013-09-25 AU AU2013322736A patent/AU2013322736A1/en not_active Abandoned
- 2013-09-25 ES ES13770441T patent/ES2791648T3/es active Active
- 2013-09-25 EP EP13770441.7A patent/EP2900657B1/en active Active
- 2013-09-25 SG SG11201502343RA patent/SG11201502343RA/en unknown
-
2015
- 2015-02-09 IL IL237159A patent/IL237159A0/en active IP Right Grant
- 2015-03-04 CL CL2015000530A patent/CL2015000530A1/es unknown
- 2015-03-06 PH PH12015500488A patent/PH12015500488A1/en unknown
- 2015-03-06 CR CR20150119A patent/CR20150119A/es unknown
- 2015-07-31 HK HK15107343.2A patent/HK1206737A1/xx unknown
-
2016
- 2016-03-30 US US15/085,164 patent/US9931323B2/en active Active
-
2018
- 2018-01-29 AU AU2018200648A patent/AU2018200648B2/en active Active
- 2018-06-04 JP JP2018106700A patent/JP2018162263A/ja active Pending
-
2020
- 2020-04-28 HR HRP20200681TT patent/HRP20200681T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL237159A0 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide cyclic ether compounds and methods of use | |
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
ZA201405248B (en) | Anesthetic compounds and related methods of use | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
ZA201406082B (en) | Use of ccr3-inhibitors | |
EP2812324A4 (en) | HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
SG11201403215TA (en) | Cyclic compounds and methods of making and using the same | |
HK1206024A1 (en) | Tricyclic compounds and methods of use therefor | |
HK1203494A1 (en) | Heteroaryl compounds and methods of use thereof | |
EP2906576A4 (en) | GLYCOSPHINGOLIPIDES AND METHOD OF USE THEREOF | |
EP2847193A4 (en) | HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF | |
IL239245A0 (en) | A new use of Eclidenium | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
EP2841164A4 (en) | COMPOSITIONS AND USE PROCEDURES FOR THE SKIN |